Sharekhan has given Buy recommendation for Lupin with a target price of Rs. ekhan is bullish on Lupin has recommended buy rating on the stock with a revised PT of 1,210 in its research report issued on Oct 28, 2021
Near term headwinds in the form of increasing raw material costs pressures and heightened competitive intensity could impact growth and exert margins pressures for Lupin. Further expected strong outlook for the domestic formulations business coupled with sturdy product pipeline expected to playout in 2HFY23 could drive the US sales, and are the key growth drivers. At CMP the stock trades at 26.8x/19.7x if FY22E and Fy23E EPS. Lupin’s long term growth levers are intact despite of near term hiccups, hence we retain Buy recommendation on the stock with a revised PT of 1210.